Morgan Stanley Remains Sidelined on Lamb Weston (LW) Following 1Q Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Lamb Weston (LW) PT Raised to $58 at Jefferies Following 1Q
October 5, 2017 7:08 AM EDTJefferies raised its price target on Lamb Weston (NYSE: LW) to $58.00 (from $53.00) while maintaining a Buy rating following the company's 1Q earnings release. Results reaffirmed positive view on industry fundamentals. Jefferies reported a $0.07 EPS beat.
Jefferies' FY18 EPS estimates are up from $2.36 to... More
Pre-Open Stock Movers 10/04: (CTMX) (CATB) (MYL) Higher; (CLSN) (MNTA) (TEVA) (ODP) Lower (more...)
October 4, 2017 9:30 AM EDTToday's Pre-Open Movers
CytomX Therapeutics, Inc., (Nasdaq: CTMX) 36.8% HIGHER; Amgen (Nasdaq: AMGN) and CytomX Therapeutics, Inc., (Nasdaq: CTMX) today announced that the companies have entered into a strategic collaboration in immuno-oncology. The companies will co-develop a CytomX Probody T-cell engaging bispecific against the Epidermal Growth Factor Receptor (EGFR), a highly validated oncology target expressed on multiple human cancer types. Probody T-cell engaging bispecifics are antibody constructs capable of directing cytotoxic T-cells in tumor microenvironments. In preclinical studies, CytomX's Probody... More
Lamb Weston (LW) Tops Q1 EPS by 8c, Reaffirms Outlook
October 4, 2017 8:33 AM EDTLamb Weston (NYSE: LW) reported Q1 EPS of $0.57, $0.08 better than the analyst estimate of $0.49. Revenue for the quarter came in at $817.5 million versus the consensus estimate of $795.61 million.
Lamb Weston reaffirmed FY outlook.
... MoreLamb Weston (LW) October 50 calls and October 45 puts active into Q1
October 3, 2017 1:45 PM EDTLamb Weston (NYSE: LW) October call option implied volatility is at 30, November is at 25; compared to its 52-week range of 19 to 101 into the expected release of Q1 results on October 4.
... More